http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020172238-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6366e39c9c52de6a92cf250c59ff815 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2020-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2460fe55c3b1fb6d057b070fbe75782c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac3e8c8b48655a8585f5cbee832a7c74 |
| publicationDate | 2020-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020172238-A1 |
| titleOfInvention | A method for predicting and monitoring the efficacy of low-dose il-2 and hydroxychloroquine therapy in autoimmune diseases and its long-term use in autoimmune-related conditions |
| abstract | A method of inhibiting or treating systemic lupus erythematosus (SLE) and/or primary Sjogren's Syndrome (pSS) in a subject in need thereof is disclosed. The method calls for administering to the subject a therapeutically effective low-dose amount of interleukin-2 and hydroxychloroquine alone or in combination with a therapeutically effective amount of another disease-modifying antirheumatic drug. That combination results in inhibiting or treating SLE and/or pSS in the subject. |
| priorityDate | 2019-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 325.